EcoDrugPlus

Cytochrome P450 26a1

Ensembl ID : ENSLBEG00000026462
Gene Symbol: LOC109987228
3 Cross references
194 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSLBEG00000005862
Gene Symbol: LOC109988265
2 Cross references
474 Possible Orthologues:

Cytochrome P450 3a30-Like

Ensembl ID : ENSLBEG00000020647
Gene Symbol: LOC109998337
2 Cross references
533 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSLBEG00000019262
Gene Symbol: LOC109996119
2 Cross references
445 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSLBEG00000020781
Gene Symbol: LOC109998338
2 Cross references
533 Possible Orthologues:

Cytochrome P450 3a40-Like

Ensembl ID : ENSLBEG00000006148
Gene Symbol: LOC109988272
3 Cross references
551 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSLBEG00000016667
Gene Symbol: CYP19A1
3 Cross references
244 Possible Orthologues:

Cytochrome P450, Family 17, Subfamily A, Polypeptide 1

Ensembl ID : ENSLBEG00000015352
Gene Symbol: CYP17A1
1 Cross references
210 Possible Orthologues:

Cytochrome P450, Family 19, Subfamily A, Polypeptide 1a

Ensembl ID : ENSLBEG00000006386
Gene Symbol: CYP19A1A
1 Cross references
249 Possible Orthologues:

Delta(24)-Sterol Reductase-Like

Ensembl ID : ENSLBEG00000010636
Gene Symbol: LOC109976996
3 Cross references
207 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSLBEG00000015781
Gene Symbol: LOC109984988
3 Cross references
197 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSLBEG00000019876
Gene Symbol: LOC109990830
3 Cross references
214 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).